Evaluation of cellular immune responses in cancer vaccine recipients: Lessons from NY-ESO-1

Expert Review of Vaccines

Volumn 9, Issue 6, 2010, Pages 617-629

  Cebon, Jonathan ^a   Knights, Ashley ^a   Ebert, Lisa ^a   Jackson, Heather ^a   Chen, Weisan ^a  

^a AUSTIN HOSPITAL   (Australia)

Author keywords

Cancer testis antigen; Cancer vaccine; CD4+ T lymphocyte; CD8 + T lymphocyte; Immune monitoring; NY ESO 1; Treg

Indexed keywords

CANCER ANTIBODY; NY ESO 1 ANTIBODY; NY ESO 1 ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; DRUG MONITORING; FETAL CALF SERUM; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE CULTURE; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SKIN TEST; STOMACH CANCER;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; INTERFERON-GAMMA; MEMBRANE PROTEINS; NEOPLASMS; SKIN TESTS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 77953245444     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.58     Document Type: Review

References (95)

1. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038), 1643-1647 (1991).
2. Slingluff CL Jr, Petroni GR, Olson W et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J. Clin. Oncol. 26(30), 4973-4980 (2008).
3. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 4, 1 (2004).
4. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5(8), 615-625 (2005).
5. Hofmann O, Caballero OL, Stevenson BJ et al. Genome-wide analysis of cancer/testis gene expression. Proc. Natl Acad. Sci. USA 105(51), 20422-20427 (2008).
6. Jackson H, Dimopoulos N, Mifsud NA et al. Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1. J. Immunol. 176(10), 5908-5917 (2006).
7. Nicholaou T, Ebert L, Davis ID et al. Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol. Cell Biol. 84(3), 303-317 (2006).
8. Gnjatic S, Nishikawa H, Jungbluth AA et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv. Cancer Res. 95, 1-30 (2006).
9. Stockert E, Jäger E, Chen Y-T et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187(8), 1349-1354 (1998).
10. Jager E, Chen YT, Drijfhout JW et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187(2), 265-270 (1998).
11. Hunder NN, Wallen H, Cao J et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358(25), 2698-2703 (2008).
12. Scanlan MJ, Gout I, Gordon CM et al. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun. 1, 4 (2001).
13. Scanlan MJ, Welt S, Gordon CM et al. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res. 62(14), 4041-4047 (2002).
14. Davis ID, Chen W, Jackson H et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proc. Natl Acad. Sci. USA 101(29), 10697-10702 (2004).
15. Jager E, Karbach J, Gnjatic S et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc. Natl Acad. Sci. USA 103(39), 14453-14458 (2006).
16. Valmori D, Souleimanian NE, Hesdorffer CS, Ritter G, Old LJ, Ayyoub M. Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses. Clin. Immunol. 117(1), 24-30 (2005).
17. Stockert E, Jager E, Chen YT et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187(8), 1349-1354 (1998).
18. Nakamura S, Nouso K, Noguchi Y et al. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 21(8), 1281-1285 (2006).
19. Tureci O, Mack U, Luxemburger U et al. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett. 236(1), 64-71 (2006).
20. Wang Y, Wu XJ, Zhao AL et al. Cancer/ testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immun. 4, 11 (2004).
21. Gnjatic S, Atanackovic D, Jager E et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc. Natl Acad. Sci. USA 100(15), 8862-8867 (2003).
22. Cebon JS, Svobodova S, Browning J et al. Prognostic impact of cancer-testis antigen expression in primary cutaneous melanoma. J. Clin. Oncol. 27(Suppl. 15) (2009) (Abstract 9004).
23. Shackleton MJ, Sturrock S, MacGreogor D et al. Indolent patterns of disease progression in melanoma patients expressing anti-NY-ESO-1 antibodies. In: Cancer Immunosurveillance 1999. Cancer Research Institute, NY, USA, 1-9 (1999).
24. Yuan J, Gnjatic S, Li H et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA 105(51), 20410-20415 (2008).
25. Barrow C, Browning J, MacGregor D et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin. Cancer Res. 12(3 Pt 1), 764-771 (2006).
26. Vaughan HA, Svobodova S, Macgregor D et al. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin. Cancer Res. 10(24), 8396-8404 (2004).
27. Jager E, Stockert E, Zidianakis Z et al. Humoral immune responses of cancer patients against 'cancer-testis' antigen NY-ESO-1: correlation with clinical events. Int. J. Cancer 84(5), 506-510 (1999).
28. Gnjatic S, Ritter E, Buchler MW et al. Seromic profiling of ovarian and pancreatic cancer. Proc. Natl Acad. Sci. USA 107(11), 5088-5093 (2010).
29. Murphy R, Green S, Ritter G et al. Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions. Prep. Biochem. Biotechnol. 35(2), 119-134 (2005).
30. Shackleton M, Davis ID, Hopkins W et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 4, 9 (2004).
31. Chen Q, Jackson H, Shackleton M et al. Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination. Cancer Immun. 5, 5 (2005).
32. Lonchay C, van der Bruggen P, Connerotte T et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl Acad. Sci. USA 101(Suppl. 2), 14631-14638 (2004).
33. Coulie PG, Connerotte T. Human tumor-specific T lymphocytes: does function matter more than number? Curr. Opin. Immunol. 17(3), 320-325 (2005).
34. Connerotte T, Van Pel A, Godelaine D et al. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res. 68(10), 3931-3940 (2008).
35. Knights AJ, Nuber N, Thomson CW et al. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunol. Immunother. 58(3), 325-338 (2009).
36. Gnjatic S, Nagata Y, Jager E et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc. Natl Acad. Sci. USA 97(20), 10917-10922 (2000).
37. Gnjatic S, Altorki NK, Tang DN et al. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin. Cancer Res. 15(6), 2130-2139 (2009).
38. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol. 16(4), 364-369 (1998). (Pubitemid 28164657)
39. Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109(3), 409-417 (2002).
40. Grunebach F, Erndt S, Hantschel M, Heine A, Brossart P. Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells. Cancer Immunol. Immunother. 57(10), 1483-1491 (2008).
41. Weide B, Carralot JP, Reese A et al. Results of the first Phase I/II clinical vaccination trial with direct injection of mRNA. J. Immunother. 31(2), 180-188 (2008).
42. Teufel R, Carralot JP, Scheel B et al. Human peripheral blood mononuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T-lymphocytes in vitro. Cell. Mol. Life Sci. 62(15), 1755-1762 (2005).
43. Kreiter S, Konrad T, Sester M, Huber C, Tureci O, Sahin U. Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA. Cancer Immunol. Immunother. 56(10), 1577-1587 (2007).
44. Naota H, Miyahara Y, Okumura S et al. Generation of peptide-specific CD8+ T cells by phytohemagglutinin-stimulated antigen-mRNA-transduced CD4+ T cells. J. Immunol. Methods 314(1-2), 54-66 (2006).
45. Yewdell JW, Anton LC, Bennink JR. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J. Immunol. 157(5), 1823-1826 (1996).
46. Bonehill A, Heirman C, Tuyaerts S et al. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. Cancer Res. 63(17), 5587-5594 (2003).
47. Fassnacht M, Lee J, Milazzo C et al. Induction of CD4+ and CD8+ T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Clin. Cancer Res. 11(15), 5566-5571 (2005).
48. Kavanagh DG, Kaufmann DE, Sunderji S et al. Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. Blood 107(5), 1963-1969 (2006).
49. Kreiter S, Selmi A, Diken M et al. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J. Immunol. 180(1), 309-318 (2008).
50. Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL. Post-translational modifications of naturally processed MHC-binding epitopes. Curr. Opin. Immunol. 18(1), 92-97 (2006).
51. Falo LD Jr, Colarusso LJ, Benacerraf B, Rock KL. Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules. Proc. Natl Acad. Sci. USA 89(17), 8347-8350 (1992).
52. Chen W, McCluskey J. Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. Adv. Cancer Res. 95, 203-247 (2006).
53. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17, 51-88 (1999).
54. Ebert LM, Liu YC, Clements CS et al. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. Cancer Res. 69(3), 1046-1054 (2009).
55. Jackson HM, Dimopoulos N, Chen Q et al. A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. J. Immunol. Methods 291(1-2), 51-62 (2004).
56. Geysen HM, Meloen RH, Barteling SJ. Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc. Natl Acad. Sci. USA 81(13), 3998-4002 (1984).
57. Gnjatic S, Jager E, Chen W et al. CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc. Natl Acad. Sci. USA 99(18), 11813-11818 (2002).
58. Bell MJ, Burrows JM, Brennan R et al. The peptide length specificity of some HLA class I alleles is very broad and includes peptides of up to 25 amino acids in length. Mol. Immunol. 46(8-9), 1911-1917 (2009).
59. Kozlowski S, Corr M, Shirai M et al. Multiple pathways are involved in the extracellular processing of MHC class I-restricted peptides. J. Immunol. 151(8), 4033-4044 (1993).
60. Chen W, Yewdell JW, Levine RL, Bennink JR. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J. Exp. Med. 189(11), 1757-1764 (1999).
61. Srivastava PK. Therapeutic cancer vaccines. Curr. Opin. Immunol. 18(2), 201-205 (2006).
62. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004).
63. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9(3), 239-244 (2008).
64. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 133(5), 775-787 (2008).
65. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol. Med. 13(3), 108-116 (2007).
66. Shevach EM. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity 30(5), 636-645 (2009).
67. Gallimore AM, Simon AK. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 27(45), 5886-5893 (2008).
68. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6(4), 295-307 (2006).
69. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004).
70. Piersma SJ, Welters MJ, van der Burg SH. Tumor-specific regulatory T cells in cancer patients. Hum. Immunol. 69(4-5), 241-249 (2008).
71. Betts GJ, Clarke SL, Richards HE, Godkin AJ, Gallimore AM. Regulating the immune response to tumours. Adv. Drug Deliv. Rev. 58(8), 948-961 (2006).
72. Francois V, Ottaviani S, Renkvist N et al. The CD4+ T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. Cancer Res. 69(10), 4335-4345 (2009).
73. Jandus C, Bioley G, Dojcinovic D et al. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer Res. 69(20), 8085-8093 (2009).
74. Vence L, Palucka AK, Fay JW et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 104(52), 20884-20889 (2007).
75. van der Burg SH, Piersma SJ, de Jong A et al. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc. Natl Acad. Sci. USA 104(29), 12087-12092 (2007).
76. Welters MJ, Kenter GG, Piersma SJ et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14(1), 178-187 (2008).
77. Bonertz A, Weitz J, Pietsch DH et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Invest. 119(11), 3311-3321 (2009).
78. Valitutti S, Muller S, Salio M, Lanzavecchia A. Degradation of T cell receptor (TCR)-CD3-z complexes after antigenic stimulation. J. Exp. Med. 185(10), 1859-1864 (1997).
79. Nicholaou T, Ebert LM, Davis ID et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin. Cancer Res. 15(6), 2166-2173 (2009).
80. Eggermont AM. Therapeutic vaccines in solid tumours: can they be harmful? Eur. J. Cancer 45(12), 2087-2090 (2009).
81. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155(4), 1063-1074 (1982).
82. Ghiringhelli F, Larmonier N, Schmitt E et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J. Immunol. 34(2), 336-344 (2004).
83. Ghiringhelli F, Menard C, Puig PE et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56(5), 641-648 (2007).
84. Henney CS. A cytolytic system for the in vitro detection of cell-mediated immunity to soluble antigen. J. Immunol. 105(4), 919-927 (1970).
85. Dimopoulos N, Jackson HM, Ebert L et al. Combining MHC tetramer and intracellular cytokine staining for CD8+ T cells to reveal antigenic epitopes naturally presented on tumor cells. J. Immunol. Methods 340(1), 90-94 (2009).
86. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65(1-2), 55-63 (1983).
87. Fischer K, Andreesen R, Mackensen A. An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity. J. Immunol. Methods 259(1-2), 159-169 (2002).
88. Betts MR, Brenchley JM, Price DA et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281(1-2), 65-78 (2003).
89. Yewdell JW. Plumbing the sources of endogenous MHC class I peptide ligands. Curr. Opin. Immunol. 19(1), 79-86 (2007).
90. Gaczynska M, Rock KL, Goldberg AL. Role of proteasomes in antigen presentation. Enzyme Protein 47(4-6), 354-369 (1993).
91. Chen W, Norbury CC, Cho Y, Yewdell JW, Bennink JR. Immunoproteasomes shape immunodominance hierarchies of antiviral CD8+ T cells at the levels of T cell repertoire and presentation of viral antigens. J. Exp. Med. 193(11), 1319-1326 (2001).
92. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10(3), 294-298 (2004).
93. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002).
94. Obar JJ, Khanna KM, Lefrancois L. Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 28(6), 859-869 (2008).
95. Janetzki S, Britten CM, Kalos M et al. 'MIATA'-minimal information about T cell assays. Immunity 31(4), 527-528 (2009).